SCHEMBL30003432

SCHEMBL30003432

CC(C)c1oc(-c2ccc(Cl)cc2Cl)nc1CCC(=O)c1ccc(OC(C)(C)CO)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 8/20 0.56
PPARA Q07869 8/20 0.56
PPARD Q03181 7/20 0.56
MAPT P10636 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
POLB P06746 3/20 0.36
HSD17B10 Q99714 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
TSHR P16473 2/20 0.36
KDM4E B2RXH2 4/20 0.34
SHMT1 P34896 1/20 0.33
SHMT2 P34897 1/20 0.33
ALDH1A1 P00352 4/20 0.33
CYP2C9 P11712 2/20 0.33
HPGD P15428 2/20 0.33
CYP2C19 P33261 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24658609 1.00 PPARG (0.56) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL24742577 0.91 PPARA (0.51) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL30003775 0.91 PPARA (0.51) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL30003927 0.90 PPARA (0.55) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL24658526 0.90 PPARA (0.55) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL1765972 0.90 PPARA (0.69) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL24658334 0.89 PPARA (0.52) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL30003512 0.89 PPARA (0.52) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL377241 0.88 PPARG (0.58) PPARGPPARAPPARDMAPTSMN1; SMN2
SCHEMBL376949 0.85 PPARG (0.51) PPARGPPARAPPARDMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333379-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2025-10-30 US disclosed
US-12297168-B2 Compounds useful for treating liver diseases ABIONYX PHARMA SA (FR) 2025-05-13 US disclosed
US-20240199575-A1 COMPOUNDS USEFUL FOR TREATING LIVER DISEASES ABIONYX PHARMA SA (FR) 2024-06-20 US disclosed
US-20230278952-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2023-09-07 US disclosed
US-11634387-B2 Compounds useful for treating liver diseases ABIONYX PHARMA SA (FR) 2023-04-25 US disclosed
US-20220363632-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2022-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278952-A1 Compounds Useful for Treating Liver Diseases SLC10A1, FABP1, CPT1A PPARG 71/4885PPARA 94/4885PPARD 332/4885
US-20240199575-A1 COMPOUNDS USEFUL FOR TREATING LIVER DISEASES SLC10A1, FABP1, CPT1A PPARG 71/4885PPARA 94/4885PPARD 332/4885
US-11634387-B2 Compounds useful for treating liver diseases SLC10A1, FABP1, CPT1A PPARG 71/4885PPARA 94/4885PPARD 332/4885
US-20250333379-A1 Compounds Useful for Treating Liver Diseases SLC10A1, FABP1, CPT1A PPARG 71/4885PPARA 94/4885PPARD 332/4885
US-12297168-B2 Compounds useful for treating liver diseases SLC10A1, FABP1, CPT1A PPARG 71/4885PPARA 94/4885PPARD 332/4885
US-20220363632-A1 Compounds Useful for Treating Liver Diseases SLC10A1, FABP1, CPT1A PPARG 71/4885PPARA 94/4885PPARD 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.